Promiscuous Shiga toxin 2e and its intimate relationship to Forssman.

Shiga toxin (Stx) 2e of Stx-producing Escherichia coli (STEC) represents the major virulence factor responsible for the pig edema disease which is characterized by hemorrhagic lesions, neurological disorders and often fatal outcomes. Stx2e-producing strains from the intestine of slaughtered pigs (n = 3), feces of piglets with postweaning diarrhea or edema disease (n = 12) and feces of humans with asymptomatic infections or mild diarrhea (n = 13) were comparatively analyzed for the binding specificities of Stx2e to glycosphingolipids (GSLs) of the globo-series. Besides equivalent binding towards globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer), we could demonstrate specific interaction of Stx2e preparations from human and porcine STEC isolates with Forssman GSL. Notably, Forssman GSL was recognized neither by structurally closely related Stx2 nor by Stx1 derived from human STEC isolates conferring Stx2e a unique recognition feature. Noteworthy, 7 (54%) of the 13 human and 8 (53%) of the 15 pig Stx2e samples exhibited cytotoxic action towards human brain microvascular endothelial cells. Our findings provide a basis for further exploring the functional role of the promiscuous receptor repertoire of Stx2e and the exact nature of the mechanisms that underlie different pathological outcomes of Stx2e-producing STEC in humans and pigs.

[1]  G. Abu-Ali,et al.  Shiga toxin 2 overexpression in Escherichia coli O157:H7 strains associated with severe human disease. , 2011, Microbial pathogenesis.

[2]  J. Matsuda,et al.  High-performance thin-layer chromatography/mass spectrometry for the analysis of neutral glycosphingolipids. , 2011, Biochimica et biophysica acta.

[3]  M. Mormann,et al.  Thin-layer chromatography, overlay technique and mass spectrometry: a versatile triad advancing glycosphingolipidomics. , 2011, Biochimica et biophysica acta.

[4]  A. Mellmann,et al.  Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. , 2011, The Lancet. Infectious diseases.

[5]  J. Rothberg,et al.  Prospective Genomic Characterization of the German Enterohemorrhagic Escherichia coli O104:H4 Outbreak by Rapid Next Generation Sequencing Technology , 2011, PloS one.

[6]  T. Boppel,et al.  Eculizumab in severe Shiga-toxin-associated HUS. , 2011, The New England journal of medicine.

[7]  A. Friedrich,et al.  Shiga toxin glycosphingolipid receptors in microvascular and macrovascular endothelial cells: differential association with membrane lipid raft microdomains[S] , 2011, Journal of Lipid Research.

[8]  R. Kannagi,et al.  Systematic analyses of free ceramide species and ceramide species comprising neutral glycosphingolipids by MALDI-TOF MS with high-energy CID , 2011, Glycoconjugate Journal.

[9]  Patrik Langehanenberg,et al.  Differential cytotoxic actions of Shiga toxin 1 and Shiga toxin 2 on microvascular and macrovascular endothelial cells , 2010, Thrombosis and Haemostasis.

[10]  K. Sandvig,et al.  Endocytosis and retrograde transport of Shiga toxin. , 2010, Toxicon : official journal of the International Society on Toxinology.

[11]  T. Obrig Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease , 2010, Toxins.

[12]  F. Schaefer,et al.  Treatment of typical (enteropathic) hemolytic uremic syndrome. , 2010, Seminars in thrombosis and hemostasis.

[13]  A. Friedrich,et al.  On the structural diversity of Shiga toxin glycosphingolipid receptors in lymphoid and myeloid cells determined by nanoelectrospray ionization tandem mass spectrometry. , 2010, Rapid communications in mass spectrometry : RCM.

[14]  A. Friedrich,et al.  Neutral glycosphingolipids in human blood: a precise mass spectrometry analysis with special reference to lipoprotein-associated Shiga toxin receptors[S] , 2010, Journal of Lipid Research.

[15]  T. Beddoe,et al.  Structure, biological functions and applications of the AB5 toxins. , 2010, Trends in biochemical sciences.

[16]  A. Mellmann,et al.  Distribution and Phylogeny of Immunoglobulin-Binding Protein G in Shiga Toxin-Producing Escherichia coli and Its Association with Adherence Phenotypes , 2010, Infection and Immunity.

[17]  M. Morigi,et al.  Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction , 2010, Pediatric Nephrology.

[18]  S. Tzipori,et al.  Shiga toxin 2-specific but not shiga toxin 1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing shiga toxin 1 and shiga toxin 2. , 2010, The Journal of infectious diseases.

[19]  V. Gannon,et al.  Verocytotoxin-producing Escherichia coli (VTEC). , 2010, Veterinary microbiology.

[20]  A. Friedrich,et al.  Shiga Toxin Receptor Gb3Cer/CD77: Tumor-Association and Promising Therapeutic Target in Pancreas and Colon Cancer , 2009, PloS one.

[21]  A. Friedrich,et al.  Shiga toxins, glycosphingolipid diversity, and endothelial cell injury , 2009, Thrombosis and Haemostasis.

[22]  M. Murata,et al.  Contribution of glycolipids to species-specific antigens on erythrocytes of several animal species as to recognition of antigens with rabbit anti-glycolipids and anti-erythrocyte antisera , 2009, Glycoconjugate Journal.

[23]  L. Beutin,et al.  Evaluation of Major Types of Shiga Toxin 2e-Producing Escherichia coli Bacteria Present in Food, Pigs, and the Environment as Potential Pathogens for Humans , 2008, Applied and Environmental Microbiology.

[24]  A. Friedrich,et al.  Matching IR-MALDI-o-TOF mass spectrometry with the TLC overlay binding assay and its clinical application for tracing tumor-associated glycosphingolipids in hepatocellular and pancreatic cancer. , 2008, Analytical chemistry.

[25]  A. Friedrich,et al.  New Immuno-PCR Assay for Detection of Low Concentrations of Shiga Toxin 2 and Its Variants , 2008, Journal of Clinical Microbiology.

[26]  A. Friedrich,et al.  Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity , 2008, Glycoconjugate Journal.

[27]  L. Beutin,et al.  Comparative evaluation of the Ridascreen® Verotoxin enzyme immunoassay for detection of Shiga‐toxin producing strains of Escherichia coli (STEC) from food and other sources , 2007, Journal of applied microbiology.

[28]  L. Beutin,et al.  Virulence profiles of Shiga toxin 2e-producing Escherichia coli isolated from healthy pig at slaughter. , 2006, Veterinary microbiology.

[29]  A. Suzuki,et al.  Convenient structural analysis of glycosphingolipids using MALDI-QIT-TOF mass spectrometry with increased laser power and cooling gas flow. , 2006, Journal of biochemistry.

[30]  Nathan Sharon,et al.  Carbohydrates as future anti-adhesion drugs for infectious diseases. , 2006, Biochimica et biophysica acta.

[31]  A. Friedrich,et al.  Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionization quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shiga toxin 1. , 2005, Rapid communications in mass spectrometry : RCM.

[32]  A. Mellmann,et al.  Shiga Toxin 2e-Producing Escherichia coli Isolates from Humans and Pigs Differ in Their Virulence Profiles and Interactions with Intestinal Epithelial Cells , 2005, Applied and Environmental Microbiology.

[33]  H. Karch,et al.  Enterohaemorrhagic Escherichia coli in human medicine. , 2005, International journal of medical microbiology : IJMM.

[34]  H. Karch,et al.  Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium , 2005, Thrombosis and Haemostasis.

[35]  G. Daube,et al.  Verotoxigenic Escherichia coli from animals, humans and foods: who's who? , 2005, Journal of applied microbiology.

[36]  P. Tarr,et al.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome , 2005, The Lancet.

[37]  A. Friedrich,et al.  Transcriptional Analysis of Genes Encoding Shiga Toxin 2 and Its Variants in Escherichia coli , 2005, Applied and Environmental Microbiology.

[38]  C. Pourcel,et al.  Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Galα1–3Gal), blood group H determinant andN-glycolylneuraminic acid , 1996, Glycoconjugate Journal.

[39]  T. Cheasty,et al.  Isolation of vero cytotoxin-producingEscherichia coli serotypes O9ab:H- and O101:H-carrying VT2 variant gene sequences from a patient with haemolytic uraemic syndrome , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[40]  B. Domon,et al.  A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates , 1988, Glycoconjugate Journal.

[41]  P. Fratamico,et al.  Prevalence and Characterization of Shiga Toxin-Producing Escherichia coli in Swine Feces Recovered in the National Animal Health Monitoring System's Swine 2000 Study , 2004, Applied and Environmental Microbiology.

[42]  J. Peter-Katalinic,et al.  Direct analysis of silica gel extracts from immunostained glycosphingolipids by nanoelectrospray ionization quadrupole time-of-flight mass spectrometry. , 2004, Analytical chemistry.

[43]  L. Beutin,et al.  Serotyping, stx2 Subtyping, and Characterization of the Locus of Enterocyte Effacement Island of Shiga Toxin-Producing Escherichia coli and E. coli O157:H7 Strains Isolated from the Environment in France , 2004, Applied and Environmental Microbiology.

[44]  L. Beutin,et al.  Characterization of Shiga Toxin-Producing Escherichia coli Strains Isolated from Human Patients in Germany over a 3-Year Period , 2004, Journal of Clinical Microbiology.

[45]  N. Sharon,et al.  Safe as mother's milk: Carbohydrates as future anti-adhesion drugs for bacterial diseases , 2000, Glycoconjugate Journal.

[46]  M A Chester,et al.  IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) Nomenclature of glycolipids: Recommendations 1997 , 1999, Glycoconjugate Journal.

[47]  N. Sharon,et al.  Developmental changes in neutral glycosphingolipids of mouse placenta , 1993, Glycoconjugate Journal.

[48]  M. Breimer,et al.  Blood group type glycosphingolipids of human kidneys. Structural characterization of extended globo-series compounds , 1991, Glycoconjugate Journal.

[49]  J. Peter-Katalinic,et al.  Discrimination of neolacto-series gangliosides with alpha2-3- and alpha2-6-linked N-acetylneuraminic acid by nanoelectrospray ionization low-energy collision-induced dissociation tandem quadrupole TOF MS. , 2003, Analytical chemistry.

[50]  S. Elliott,et al.  Forssman Synthetase Expression Results in Diminished Shiga Toxin Susceptibility , 2003, Infection and Immunity.

[51]  A. Friedrich,et al.  Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. , 2002, The Journal of infectious diseases.

[52]  H Nakajima,et al.  Kinetic Analysis of Binding between Shiga Toxin and Receptor Glycolipid Gb3Cer by Surface Plasmon Resonance* , 2001, The Journal of Biological Chemistry.

[53]  T. Cheasty,et al.  Evaluation of a reversed passive latex agglutination test for the detection of Verocytotoxin (VT) expressed by strains of VT‐producing Escherichia coli , 2001, Letters in applied microbiology.

[54]  T. Voss,et al.  The AIDA Autotransporter System Is Associated with F18 and Stx2e in Escherichia coli Isolates from Pigs Diagnosed with Edema Disease and Postweaning Diarrhea , 2001, Clinical Diagnostic Laboratory Immunology.

[55]  S. Miyoshi,et al.  Reduction of the major xenoantigen on glycosphingolipids of swine endothelial cells by various glycosyltransferases. , 2000, Glycobiology.

[56]  S. Elliott,et al.  Characterization of the Human Forssman Synthetase Gene , 1999, The Journal of Biological Chemistry.

[57]  J. Mainil,et al.  Shiga/verocytotoxins and Shiga/verotoxigenic Escherichia coli in animals. , 1999, Veterinary research.

[58]  M.Alan Chester,et al.  IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids--recommendations 1997. , 1998, European journal of biochemistry.

[59]  Jcbn Nomenclature of glycolipids , 1998 .

[60]  S. Lauwers,et al.  Identification of New Verocytotoxin Type 2 Variant B-Subunit Genes in Human and Animal Escherichia coliIsolates , 1998, Journal of Clinical Microbiology.

[61]  J. Müthing TLC in structure and recognition studies of glycosphingolipids. , 1998, Methods in molecular biology.

[62]  J. Peter-Katalinic,et al.  Isolation and structural characterization of glycosphingolipids of in vitro propagated bovine aortic endothelial cells. , 1997, Glycobiology.

[63]  F. Gilles,et al.  Selective expression of adhesion molecules on human brain microvascular endothelial cells , 1997, Journal of Neuroimmunology.

[64]  C. Lingwood,et al.  Comparative cytotoxicity of purified Shiga-like toxin-IIe on porcine and bovine aortic endothelial and human colonic adenocarcinoma cells. , 1996, Journal of medical microbiology.

[65]  J. Baenziger,et al.  Expression cloning of Forssman glycolipid synthetase: a novel member of the histo-blood group ABO gene family. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[66]  C. Lingwood,et al.  Interaction of verotoxin 2e with pig intestine , 1996, Infection and immunity.

[67]  C. Lingwood Role of verotoxin receptors in pathogenesis. , 1996, Trends in microbiology.

[68]  J. Lehmann,et al.  Isolation and structural characterization of fucosylated gangliosides with linear poly-N-acetyllactosaminyl chains from human granulocytes. , 1996, Glycobiology.

[69]  A. Caprioli,et al.  Clonal relatedness of Shiga-like toxin-producing Escherichia coli O101 strains of human and porcine origin , 1995, Journal of clinical microbiology.

[70]  D. Acheson,et al.  Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e , 1995, Infection and immunity.

[71]  J. Marks,et al.  p53 in Human Cancer , 1995 .

[72]  J. Peter-Katalinic,et al.  Different Distributions of Glycosphingolipids in Mouse and Rabbit Skeletal Muscle Demonstrated by Biochemical and Immunohistological Analyses , 1994 .

[73]  G. Tyrrell,et al.  Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs , 1993, The Journal of experimental medicine.

[74]  H. Lior,et al.  Diarrhoea associated with Escherichia coli producing porcine oedema disease verotoxin , 1991, The Lancet.

[75]  C. Lingwood,et al.  Globotetraosylceramide is recognized by the pig edema disease toxin. , 1989, The Journal of biological chemistry.

[76]  C. MacKenzie,et al.  Cloning and nucleotide sequence analysis of the genes determining verocytotoxin production in a porcine edema disease isolate of Escherichia coli. , 1988, Microbial pathogenesis.

[77]  M. P. Jackson,et al.  Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine , 1988, Journal of bacteriology.

[78]  B. Domon,et al.  Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry. , 1988, Biochemistry.

[79]  P. Mühlradt,et al.  Forssman glycolipid, an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes. , 1987, Journal of immunology.

[80]  H. Egge,et al.  Structural characterization of gangliosides from murine T lymphocytes. , 1987, European journal of biochemistry.

[81]  P. Mühlradt,et al.  An improved semi-quantitative enzyme immunostaining procedure for glycosphingolipid antigens on high performance thin layer chromatograms. , 1986, Journal of immunological methods.

[82]  K. Karlsson,et al.  Isoglobotriaosylceramide and the Forssman glycolipid of dog small intestine occupy separate tissue compartments and differ in ceramide composition. , 1983, Biochimica et biophysica acta.

[83]  Joshua Jortner,et al.  Nomenclature of retinoids: recommendations 1981. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). , 1983, Archives of biochemistry and biophysics.

[84]  R. Yu,et al.  Gangliosides: structure, isolation, and analysis. , 1982, Methods in enzymology.

[85]  M. Breimer,et al.  Blood group type glycosphingolipids from the small intestine of different animals analysed by mass spectrometry and thin-layer chromatography. A note on species diversity. , 1981, Journal of biochemistry.

[86]  R. Yu,et al.  Gangliosides of human, cat, and rabbit spinal cords and cord myelin. , 1978, Journal of lipid research.

[87]  S. Roy,et al.  A rapid and quantitative method for the isolation of gangliosides and neutral glycosphingolipids by DEAE-silica gel chromatography. , 1978, Journal of lipid research.

[88]  J Konowalchuk,et al.  Vero response to a cytotoxin of Escherichia coli , 1977, Infection and immunity.

[89]  S. Hakomori,et al.  Isoantigenic expression of Forssman glycolipid in human gastric and colonic mucosa: its possible identity with "A-like antigen" in human cancer. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[90]  M. F. Mallette,et al.  Sheep erythrocyte Forssman hapten, an isohapten system: composition of the ceramide. , 1975, Immunochemistry.

[91]  M. F. Mallette,et al.  Structure of Forssman hapten glycosphingolipid from sheep erythrocytes. , 1974, Immunochemistry.

[92]  K. Karlsson,et al.  Characterization of the forssman glycolipid hapten of horse kidney by mass spectrometry. , 1974, The Journal of biological chemistry.

[93]  S. Hakomori,et al.  A revised structure for the Forssman glycolipid hapten. , 1971, The Journal of biological chemistry.

[94]  T. Saito,et al.  Quantitative isolation of total glycosphingolipids from animal cells. , 1971, Journal of lipid research.